Here are some things STAT will be watching for during Wednesday’s hearing: Health secretary Robert F. Kennedy Jr. and Paul ...

Growing awareness of a painful endocrine disorder now named PMOS is good news for women of color, who have high prevalence ...

Regulators at the FDA have reiterated concerns that Replimmune does not have adequate data to support an approval of its ...

One year after launching the CMS Health Tech Ecosystem, officials convened in D.C. to celebrate the Trump administration ...

The big takeaway from the recent Alzheimer’s Association International Conference in London is an economic message: Dementia ...

The world risks a resurgence of the HIV epidemic after international financing to combat the disease suffered a “profound ...

Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77. Rarely has a new technology so squarely ...

Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. LONDON — Half a year into taking ...

Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. Argenx said Monday it would buy ...

Allison covers what hot startups are getting up to, and who’s financing them. She is also co-host of the weekly biotech podcast, “The Readout Loud.” You can reach Allison on Signal at AllisonDeAngelis ...

THC drinks, which have exploded in popularity in recent years, are sold in retail stores beside sodas, iced tea, and even ...

Oak Hill Bio, a new company backed by RA Capital and other investors, will take on Ultragenyx and Ionis in developing an ...